(In the report sent at 13:08 on January 16, the last sentence of the first paragraph was clarified. Eylea 8 milligrams is approved in the EU for nAMD and DMO for treatment intervals of up to six months.)
BERLIN (dpa-AFX) - Bayer can now market the high-dose version of its eye medication Eylea in the European Union for a third indication. The European Commission has approved the 8-milligram dose for the treatment of patients with macular edema following retinal vein occlusion (RVO), the pharmaceutical and agrochemical group announced on Friday. Eylea is one of the most important revenue drivers in the DAX-listed company's pharmaceuticals division and, in the 8-milligram dose, is already available in the EU for treatment intervals of up to six months for neovascular (wet) age-related macular degeneration (nAMD) as well as diabetic macular edema (DMO).
With a longer treatment interval—that is, the pause between two treatments—such eye medications become more attractive for patients, as they must be injected directly into the eye. Swiss pharmaceutical company Roche has a competing product on the market with Vabysmo./mis/stk
